Y-101D by Wuhan YZY Biopharma for Metastatic Colorectal Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Y-101D overview

Bi-specific monoclonal antibody is under development for the treatment of metastatic or locally advanced solid tumors, gastric cancer, metastatic colorectal cancer and metastatic hepatocellular carcinoma. The drug candidates are developed based on tumor therapeutic diabody (YBODY) platform. The therapeutic candidate acts by targeting programmed death-ligand 1 (PD-L1) and transforming growth factor-beta receptor (TGFb). It is administered through intravenous route.

Wuhan YZY Biopharma overview

Wuhan YZY Biopharma (YZY Biopharma) operates as a biotechnology company that develops medicines for cancer treatment. The company’s product pipeline include Y101D- PD-L1×TGF-ß is fot the treatment of bispecific antibody, Y150-CD38×CD3 is for specific antibody, Y2019 – RBD dimer subunit SARS-CoV-2 vaccine, M802 – HER2×CD3 bispecific antibody, Y400- VEGFxANG2 is for bispecific antibody, M701- relapsed or refractory multiple myeloma, Y101D is for the treatment of colorectal cancer, small cell lung cancer among others. It operates through its research and development lab, process development lab, analytical and quality center and a cGMP clinical production facility. YZY Biopharma is headquartered in Wuhan, Hubei, China.

For a complete picture of Y-101D’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.